Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants
Article
[키워드] acting
acute respiratory syndrome
Administered
administration
antibody
approved
B.1.1.529
breadth
cell line
cGMP
characterized
coronavirus
COVID-19
CRIPT
DARPA
defined
diagnosed
domains
Emergency use
FDA
H2L2 mice
Harbor
human clinical trials
human IgG1
intranasal
intranasally
intravenous
intravenously
K18-hACE2 transgenic mice
LALA
limit
lineages
Live virus
lung titer
NAb
neutralization assays
Neutralizing
Neutralizing activity
neutralizing antibody
omicron
Omicron BA.1
Omicron BA.1.1
Omicron BA.2
Pre-clinical research
provided
pseudotype
quantitation
reduced
required
retained
SARS-CoV-2
SARS-CoV-2 neutralizing antibody
SARS-CoV-2 spike
subset
tested
therapeutic
Therapies
treat
vaccination
variant
variants of concern
variants of concern.
virus
weight loss
[DOI] 10.1016/j.medj.2022.08.002 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.medj.2022.08.002 PMC 바로가기 [Article Type] Article